Across large, real-world populations with diabetes, hypertension, and obesity, participation in RPM has produced substantial and sustained clinical improvements – reductions in TCOC and physiological measures, such as fasting blood glucose, systolic and diastolic blood pressure, and meaningful weight loss. These improvements scale with both engagement intensity and program duration. Findings suggest that RPM functions as a therapeutically active intervention rather than a passive monitoring tool.
- BP Variability and HTN Control Under Continuous RPM: Demonstrates that day-to-day systolic blood pressure variability (~11 mmHg) persists despite significant reductions in mean BP, confirming the lack of reliability in relying solely on infrequent in-office readings. When RPM is paused, there is regression of BP control. However, upon re-initiation, patients experience full recovery . This strongly suggests a causal, mechanistic effect of RPM.
- Glycemic Control and Health Equity Under Remote Patient Monitoring: Presents longitudinal results from approximately 1,000 diabetic patients showing an average –30.7 mg/dL reduction in fasting glucose (p < 0.0001), with engagement- and duration-dependent effects sustained over 24 months. These benefits were equitable across socioeconomic strata, with no attenuation in lower-income quartiles.
These outcomes clearly show that RPM consistently delivers quantifiable, reproducible, and durable improvements in glycemic control, blood pressure, and weight, validated through high-frequency, real-world monitoring, while providing equitable benefits across populations. Collectively, these findings position RPM as a proven, data-rich, and economically justified framework for chronic disease management, fully aligned with the goals of value-based care and long-term cost containment.
Read more here.